← All indications
Spondylitis
Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions.
Subtype terms (3)
More specific conditions that are subtypes of Spondylitis in the MeSH hierarchy.
- Discitis
- Spondylarthritis
12 drugs (8 approved, 4 experimental)
- Tuberculosis, Spinal
5 drugs (4 approved, 1 experimental)
Drugs by status
Approved for this indication (10)
Phase 4 trials (2)
Phase 3 trials (3)
Phase 2 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (39)
- Abbott
- Centocor
- Merck
- Pfizer
- Wyeth
- Novartis
- Aarhus University
- Bnai Zion Medical Center
- Chung Shan Medical University
- Institut National de la Santé Et de la Recherche Médicale, France
- Rheumatism Foundation Hospital
- Shaoxing Second Hospital
- Universidade Nova de Lisboa
- Chinese University of Hong Kong
- Columbia University
- Fudan University
- Peking University
- Wenzhou Medical University
- University of Copenhagen
- Zhejiang University
- Health and Family Planning Commission of Guangdong
- Jiao Tong University
- François Rabelais University
- University of Toulouse
- Southern Medical University
- J. Dietl Hospital, Krakow
- Sun Yat-Sen University
- Government of China
- Ruhr University Bochum
- University of Sao Paulo
- +9 more
Organization Involved with Phase 3 Indications (56)
- Eisai
- UCB
- Immunex
- Celgene
- Galapagos NV
- Amgen
- Roche
- Gilead Sciences
- Schering-Plough
- Eli Lilly
- Biocad
- Biothera
- Corporacion Parc Tauli
- Hengrui Therapeutics, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Parexel
- POZEN
- Sunshine Lake Pharma Co., Ltd.
- Sun Pharmaceuticals
- Boehringer Ingelheim
- Otsuka
- TSH Biopharm Corporation Limited
- Spanish Foundation of Rheumatology
- Ajou University
- Dong-A University
- Gachon University
- Guangzhou Medical University
- Hanyang University
- Hoosier Cancer Research Network
- Hospital Universitario Central de Asturias
- +26 more
Organization Involved with Phase 2 Indications (23)
- AbbVie
- Regeneron
- Bristol-Myers Squibb
- Advanced Accelerator Applications
- Sanofi
- AmpliPhi Biosciences Corporation
- Array BioPharma
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Iltoo Pharma
- Shanghai Pharmaceuticals Holding Co., Ltd
- National Center for Research Resources (NCRR)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of London
- Oregon Health and Science University
- Saratov State Medical University
- University of Lausanne
- University of Rochester
- University of Zurich
- University of California, San Francisco
- University of Tabriz
- Tabriz Medical University
- University of Alabama, Birmingham
- University of Paris
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (7)